• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

    4/3/25 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRSP alert in real time by email

    ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET.

    A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

    About CRISPR Therapeutics

    Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

    Investor Contact:

    +1-617-307-7503

    [email protected]

    Media Contact:

    +1-617-315-4493

    [email protected]



    Primary Logo

    Get the next $CRSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRSP

    DatePrice TargetRatingAnalyst
    2/14/2025$60.00 → $99.00In-line → Outperform
    Evercore ISI
    2/12/2025$35.00Sell → Hold
    TD Cowen
    2/3/2025$65.00Buy
    H.C. Wainwright
    8/6/2024$88.00 → $84.00Buy
    Needham
    8/2/2024$90.00Buy
    Rodman & Renshaw
    6/28/2024Neutral
    Guggenheim
    2/15/2024Peer Perform
    Wolfe Research
    12/11/2023$30.00Market Perform → Underperform
    TD Cowen
    More analyst ratings

    $CRSP
    SEC Filings

    See more
    • CRISPR Therapeutics AG filed SEC Form 8-K: Other Events

      8-K - CRISPR Therapeutics AG (0001674416) (Filer)

      6/26/25 7:08:02 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics AG filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CRISPR Therapeutics AG (0001674416) (Filer)

      6/9/25 4:33:09 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by CRISPR Therapeutics AG

      424B5 - CRISPR Therapeutics AG (0001674416) (Filer)

      5/19/25 5:10:45 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CRISPR Therapeutics upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously

      2/14/25 8:06:15 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CRISPR Therapeutics upgraded by TD Cowen with a new price target

      TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00

      2/12/25 7:01:19 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on CRISPR Therapeutics with a new price target

      H.C. Wainwright initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $65.00

      2/3/25 7:05:27 AM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: New insider Morrison Briggs claimed ownership of 5,209 shares (SEC Form 3)

      3/A - CRISPR Therapeutics AG (0001674416) (Issuer)

      6/10/25 5:31:03 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director George Simeon

      4 - CRISPR Therapeutics AG (0001674416) (Issuer)

      6/6/25 5:47:02 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Behbahani Ali

      4 - CRISPR Therapeutics AG (0001674416) (Issuer)

      6/6/25 5:38:03 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Greene John bought $313,948 worth of shares (7,000 units at $44.85) (SEC Form 4)

      4 - CRISPR Therapeutics AG (0001674416) (Issuer)

      2/28/25 5:35:05 PM ET
      $CRSP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care